Nitric Oxide Nasal Spray Prevents SARS-CoV-2 Transmission

British Columbia-based SaNOtize Research & Development Corp. announced on March 15, 2021, results of clinical trials indicating that SaNOtize’s Nitric Oxide Nasal Spray (NONS) represents a safe and effective antiviral treatment that could prevent transmission of the coronavirus that causes COVID-19, shorten its course, and reduce the severity of symptoms and damage in those already infected.

The majority of the patients in the study had been infected with the UK variant, which is considered a variant of concern.

In a randomized, double-blind, placebo-controlled Phase 2 trial that evaluated 79 confirmed cases of COVID-19, SaNOtize’s NONS early treatment for COVID-19 significantly reduced the level of SARS-CoV-2, including in patients with high viral loads. The average viral log reduction in the first 24 hours was 1.362, which corresponds to a decline of about 95%.

Within 72 hours, the viral load dropped by more than 99%.

There were no adverse health events recorded in the UK trial or in over 7,000 self-administered treatments given in earlier Canadian clinical trials. NONS is not a monoclonal antibody treatment.

SaNOtize Research & Development Corp. is a biotech company based in Vancouver, BC.